After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
ARQT belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Arcutis Biotherapeutics Inc is $1.10B. A total of 1.61 million shares were traded on the day, compared to an average of 2.85M shares.
In the most recent transaction, Watanabe Todd Franklin bought 14,487 shares of ARQT for 9.02 per share on Aug 02 ’24. In a previous transaction on Aug 02 ’24, Matsuda Masaru bought 5,220 shares at 9.02 per share.
Among the insiders who sold shares, Watanabe Todd Franklin disposed of 14,487 shares on Aug 02 ’24 at a per-share price of $9.02. This resulted in the insider holding 846,263 shares of ARQT after the transaction. In another insider transaction, Burnett Patrick sold 13,206 shares at $9.02 per share on Aug 02 ’24. Company shares held by the insider now total 196,587.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ARQT has a high of $13.17 and a low of $1.76.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $1.95, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.50.
